Bausch + Lomb is an eye health company. Co. operates in three segments: Vision Care/Consumer Health Care, which includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins; Ophthalmic Pharmaceuticals, which consists of a line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, dry eyes and retinal diseases; and Surgical, which consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts and vitreous and retinal eye conditions. The BLCO average annual return since 2022 is shown above.
The Average Annual Return on the BLCO average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BLCO average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BLCO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|